Prevalence of HLA B27 in Patients Diagnosed with Ankylosing Spondylitis (AS) in Diyarbakır, Southeastern Region of Turkey.


Journal

Nigerian journal of clinical practice
ISSN: 1119-3077
Titre abrégé: Niger J Clin Pract
Pays: India
ID NLM: 101150032

Informations de publication

Date de publication:
01 Jan 2024
Historique:
received: 05 04 2023
accepted: 23 07 2023
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 5 2 2024
Statut: ppublish

Résumé

The research to be conducted on human leukocyte antigen (HLA)-B27 in patients diagnosed with ankylosing spondylitis (AS) in Diyarbakır between 2019-2021 is to contribute to the understanding of the prevalence and effect of this genetic marker in the local population. As a researcher working on HLA-B27 and AS, our focus is to research the following. HLA-B27 Prevalence: To determine the prevalence of HLA-B27 in patients diagnosed with AS during the specified period in Diyarbakır. This information can provide insight into the genetic factors associated with the disease in the local population. Disease Severity: Investigate the relationship between HLA-B27 positivity and severity of AS symptoms. To examine factors such as disease progression, pain levels, functional impairment, and quality of life in HLA-B27 positive patients compared to HLA-B27 negative patients. By Genetic Associations: To enable the discovery of potential genetic relationships between HLA-B27 and other genetic markers known to be associated with AS. To investigate whether there are any specific genetic variants associated with HLA-B27 that contribute to disease susceptibility or severity. Researchers: We recommend considering the following approaches to generate knowledge on this topic globally: Literature Review: Conducting a comprehensive review of the available scientific literature on HLA-B27 and AS. It is to describe relevant studies conducted globally and summarize their findings to provide a broader understanding of the subject. Collaboration and Data Sharing: To encourage cooperation with researchers from other regions or countries doing similar studies on HLA-B27 and ASs. By sharing our data and collaborating on analysis, we can improve the global perspective and generalizability of your findings. International Conferences and Journals: Presenting our research findings at international conferences focusing on rheumatology, genetics or related fields. To disseminate our findings globally is to submit your research articles to reputable journals specializing in AS or genetic studies. Online Platforms: Using online platforms such as Researchgate.net, academia.edu or social media networks to share our research findings, connect with other researchers in the field and participate in discussions on a global scale. By using these fields, it is possible to contribute to the global knowledge and understanding of the relationship between HLA-B27 and AS. It is also to obtain insights from studies carried out in other regions. 198 (104 male and 94 female) patients who applied to Dicle University Faculty of Medicine Physical Therapy and Rehabilitation Clinic with AS symptoms between 2019-2021 and were referred to Dicle University Medical Biology and Genetics Department for evaluation. HLA-B27 positivity was included in our study as a case group. As the control group, 50 people (25 males, 25 females) were selected among the unrelated people who applied to our laboratory to be a bone marrow donor. In both groups, DNA isolation was performed from peripheral blood using the salt precipitation method. Rotar Gene Q device was used for real-time PCR analysis. As a statistical method in analysis; The prevalences of the variables of interest were calculated. The lower and upper limits of 95% were determined as the confidence interval. According to the presence of HLA 27 positivity, the mean of ESR, CRP, and age variables were compared. Mann-Whitney U test was used due to the small number of subjects. Also, correlations between ESR and CRP were calculated. Spearman rho correlation statistics were used as a statistical method. Analyzed. Radiological examinations and laboratory tests were performed on 198 patients with suspicion AS and 50 healthy control group of 248 subjects. The prevalence of those with a definite diagnosis of AS was calculated as statistical analysis recalculated 20.16 (95% CI: 0.76-0.9552). The prevalence of HLA-B27 in 50 patients diagnosed with AS as a result of radiological examinations and laboratory tests was calculated as 92%. Our study is the first study covering the province of Diyarbakır in the Southeastern Anatolia Region, which we think will contribute to the literature in the evaluation of HLA-B27 positivity in AS patients. The prevalence of HLA-B27 in our region is higher than the prevalence in Turkey.

Identifiants

pubmed: 38317032
doi: 10.4103/njcp.njcp_258_23
pii: 01253091-202401000-00005
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-34

Informations de copyright

Copyright © 2024 Copyright: © 2024 Nigerian Journal of Clinical Practice.

Références

Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Elsevier Saunders, Philadelphia, 2014; 199–337.
Uçar F, OvalıE,Değer O, Önder E, Kartı SS. MHC gen kompleksi ve HLA doku tiplemesi testlerinin önemi. İbni Sina Tıp Dergisi 2001;6:117–24.
Mizuki N, Kimura M. [Gene structure of the human MHC region. Nihon Rinsho 1996;54:1705–17.
Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 2006;20:401–17.
Goodall JC, Gaston JS. How does HLA-B27 affect susceptibility to spondyloarthropathy?. Future Rheumatol 2006;1:189–97.
Reveille JD, Arnett FC. Spondyloarthritis:Update on pathogenesis and management. Am J Med 2005;118:592–603.
Khan MA, Mathieu A, Sorrentino R, Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 2007;6:183–9.
Tertti R, Toivanen P. Immune functions and inflammatory reactions in HLA-B27 positive subjects. Ann Rheum Dis 1991;50:731–4.
Abdelrahman MH, Mahdy S, Khanjar IA, Siam AM, Malallah HA, Al-Emadi SA, et al. Prevalence of HLA-B27 in patients with ankylosing spondylitis in Qatar. Int J Rheumatol 2012;2012:860213.
van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241–9.
Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum 2005;53:850–5.
Attili R, Hussein A, Odeh H, Hejaz H. Prevalence and comparison of HLA-B27 among ankylosing spondylitis patients in Palestine and Arab population. J Clin Med 2018;2:1–4.
Bodur H, Ataman S, Buğdaycı DS, Rezvani A, Nas K, Uzunca K, et al. Description of the registry of patients with ankylosing spondylitis in Turkey:TRASD-IP. Rheumatol Int 2012;32:169–76.
Onen F, Akar S, Birlik M, Sari I, Khan MA, Gurler O, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008;35:305–9.
Birinci A, Bilgici A, Kuru O, Durupinar B. HLA-B27 polymorphism in Turkish patients with ankylosing spondylitis. Rheumatol Int 2006;26:285–7.
Khan MA. Ankylosing spondylitis--the history of medical therapies. Clin Exp Rheumatol 2002;20 (6 Suppl 28):S3–5.
Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci 1998;316:239–49.
Özdemirel A, Tecer D, Torgutalp Ş, Küçükşahin O. Prevalence of HLA-B27 in Turkish patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Fiziksel Tip ve Rehabilitasyon Bilimleri Dergisi 2021;24:17–22.
Fırat SN, Yazıcı A, Yılmazer B, Coşan F, Savlı H, Cefle A. Low frequency of HLA-B27 in ankylosing spondylitis and its relationship with clinical findings in patients from Turkey. Eur J Rheumatol 2017;4:268–71.
Karkucak M, Çakırbay H, Çapkın E, Topbaş M, Guler M, Tosun M, Baltacı D. The Prevalence Of Ankylosing Spondylitis In The Eastern Black Sea Region Of Turkey. European Journal of General Medicine 2011;8:2.
Acar M, Cora T, Tunc R, Acar H. HLA-B27 subtypes in Turkish patients with ankylosing spondylitis and healthy controls. Rheumatol Int 2012;32:3103–5.
Pekacar FS, Akdoğan A, Hayran M, Çolak R, Yılmaz E. Association of HLA-B27, MEFV gene mutations, ERAP1, IL12B and IL23R gene polymorphisms with ankylosing spondylitis. Turkish J Biochem 2014;39:482–7.
Diyarbakır E, Eyerci N, Uzkeser H, Karatay S, Topçu A, Yildirim K, et al. The distribution of HLA B27 in patients with ankylosing spondylitis in Eastern Anatolia. J Inonu Univ Med Fac 2012;19:23–5.
Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 2008;75:299–302.
Gül A, Uyar FA, Inanç M, Ocal L, Barrett JH, Aral O, et al. A weak association of HLA-B *2702 with Behçet's disease. Genes Immun 2002;3:368–72.
Kim TJ, Kim TH. Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine 2010;77:235–40.
Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002;17:669–73.
Kim TJ, Na KS, Lee HJ, Lee B, Kim TH. HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol 2009;27:574–9.
Yang M, Xu M, Pan X, Hu Z, Li Q, Wei Y, et al. Epidemiological comparison of clinical manifestations according to HLA-B *27 carrier status of Chinese ankylosing spondylitis patients. Tissue Antigens 2013;82:338–43.
Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000;59:883–6.
Kim TJ, Kim TH. Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine 2010;77:235–40.
Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis:Is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?. Rheumatology (Oxford) 1999;38:878–82.
Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis 2011;70 (Suppl 1):i44–50.
Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241–9.
Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, et al. Susceptibility to ankylosing spondylitis in twins:The role of genes, HLA, and the environment. Arthritis Rheum 1997;40:1823–8.
Akassou A, Bakri Y. Does HLA-B27 Status influence ankylosing spondylitis phenotype?. Clin Med Insights Arthritis Musculoskelet Disord 2018;11:1–6.
Van Gaalen FA, Verduijn W, Roelen DL, Böhringer S, Huizinga TW, van der Heijde DM, et al. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Ann Rheum Dis 2013;72:974–8.
Reeves E, Elliott T, James E, Edwards CJ. ERAP1 in the pathogenesis of ankylosing spondylitis. Immunol Res 2014;60:257–69.
Wei JC, Sung-Ching HW, Hsu YW, Wen YF, Wang WC, Wong RH, et al. Interaction between HLA-B60 and HLA-B27 as a better predictor of ankylosing spondylitis in a taiwanese population. PLoS One 2015;10:e0137189.

Auteurs

D Oral (D)

Department of Medical Biology and Genetics, Dicle University, Diyarbakır, Turkey.

G G Erdal (GG)

Department of Medical Biology and Genetics, Dicle University, Diyarbakır, Turkey.

S Tekeş (S)

Department of Medical Biology and Genetics, Dicle University, Diyarbakır, Turkey.

I Yücel (I)

Department of Medical Biology and Genetics, Dicle University, Diyarbakır, Turkey.

S Em (S)

Department of Physical Therapy and Rehabilitation, Dicle University, Diyarbakır, Turkey.

Classifications MeSH